If you're one of the roughly 33 million Americans enrolled in a Medicare Advantage plan in 2026, you've probably encountered prior authorization at least once — that process where your insurance plan must approve a procedure, specialist visit, or prescription before you can receive it. A new fight in Washington is now centered on whether artificial intelligence should be making those approval decisions, and the outcome could directly shape how your care gets managed going forward.
The Centers for Medicare & Medicaid Services has been developing a pilot program called WISeR — short for Widely Integrated Systematic Evidence Review — that would use AI algorithms to evaluate and process prior authorization requests submitted by Medicare Advantage plans. CMS has framed the pilot as a way to speed up reviews and apply more consistent clinical criteria across the board. A growing coalition of House and Senate Democrats sees it very differently, and they're moving to block the program before it launches, arguing that CMS has not provided adequate transparency about how the system works or what safeguards would prevent it from accelerating wrongful denials.
The concern driving that opposition is grounded in documented evidence, not speculation. A 2022 report from the HHS Office of Inspector General examined Medicare Advantage prior authorization denials and found that plans denied 13% of requests that actually met Medicare's own coverage criteria — meaning those denials were inappropriate by the federal government's own standard. The report reviewed a sample of denials from 2019 and estimated that tens of thousands of beneficiaries each year were being wrongly denied care they were legally entitled to receive. If an AI system is trained on historical denial patterns or calibrated to contain costs, critics argue it could replicate and scale that problem far beyond what any human review team could produce.
This concern is not hypothetical. In 2023, a federal lawsuit against UnitedHealth Group alleged that the company used an AI model called nH Predict to systematically deny post-acute care claims for Medicare Advantage enrollees, with the algorithm reportedly overriding physician recommendations at a high rate. UnitedHealth disputed the characterization of the tool, but the lawsuit drew national attention to the fact that AI systems are already quietly influencing coverage decisions in Medicare Advantage — often without beneficiaries knowing it. The WISeR pilot would represent CMS formally endorsing AI-driven review at the federal level, which is why opponents are treating it as a significant policy threshold rather than a routine administrative experiment.
For beneficiaries, the practical stakes are concrete. Prior authorization requirements in Medicare Advantage cover a wide range of services: inpatient hospital stays, skilled nursing facility care, home health services, durable medical equipment, specialty drugs, and certain imaging procedures including MRIs and PET scans. In 2026, the average Medicare Advantage plan requires prior authorization for more service categories than traditional Medicare, which is one of the structural trade-offs of the lower premiums many MA plans advertise. When prior authorization works smoothly, it's a manageable administrative step. When it fails, it can mean delayed surgeries, interrupted rehabilitation stays, or denied medications — sometimes during an acute medical crisis when time is the most critical variable.
Under current federal rules, Medicare Advantage plans must respond to standard prior authorization requests within 14 calendar days and within 72 hours for expedited requests when a delay would seriously jeopardize your health. The Improving Seniors' Timely Access to Care Act, signed into law in 2022, added additional requirements: MA plans must establish electronic prior authorization systems, publicly report their approval and denial rates, and apply "gold carding" exemptions for physicians who have demonstrated consistent, appropriate ordering patterns. Those rules govern the timeline and transparency of the process. What they do not govern is the underlying decision-making engine — and if WISeR becomes that engine, the critical question is whether an AI system will apply clinical criteria the way a trained human medical reviewer would, or whether it will optimize for something else.
The Democrats leading the opposition argue that CMS has not disclosed enough about how WISeR's algorithms are built, what data they are trained on, or how the system handles complex medical situations that don't fit neatly into standardized criteria. That is a legitimate concern in healthcare AI. So-called black-box models can produce outcomes that are difficult to explain or challenge after the fact. If a human reviewer denies your prior authorization request, that reviewer can walk through the clinical reasoning step by step. If an algorithm denies it, the appeals process becomes more complicated to navigate — even if your legal right to appeal remains exactly the same.
CMS has described WISeR as a decision-support tool, meaning it would theoretically assist human reviewers rather than replace them entirely. But patient advocates and the lawmakers opposing the pilot point out that in high-volume operational environments, when an AI system flags a request as approvable or deniable, human reviewers frequently defer to that recommendation — particularly when they are processing hundreds of requests per day under time pressure. The practical distinction between AI-assisted and AI-decided can blur quickly, which is why the framing of WISeR as merely a pilot does not fully reassure the program's critics.
Every Medicare Advantage enrollee should understand their appeal rights clearly, regardless of how this legislative fight resolves. If your plan denies a prior authorization request, you have a federally protected right to appeal. For standard appeals, your plan must issue a decision within 30 days. For expedited appeals — which you can request whenever waiting would put your health at serious risk — the deadline is 72 hours. If your plan upholds the denial, you can escalate to an independent review organization, then to an administrative law judge. In 2026, the threshold for requesting an ALJ hearing is $180 or more in disputed benefits. If the ALJ rules against you, you can escalate further to the Medicare Appeals Council and ultimately to federal district court. These rights are established in federal statute and cannot be waived or modified by any plan, regardless of whether the initial denial was generated by a human reviewer or an AI system.
From a broader policy standpoint, the Democratic effort to block WISeR reflects a structural tension that has defined Medicare Advantage regulation for years. MA plans are administered by private insurers — companies including UnitedHealth, Humana, CVS/Aetna, and Cigna — that receive fixed monthly capitation payments from CMS for each enrollee. Because those payments are set in advance, plans have a direct financial incentive to manage utilization carefully, and prior authorization is one of the primary mechanisms for doing that. CMS has been working to rein in inappropriate denials through new oversight rules and public reporting requirements. The WISeR pilot, in the eyes of its critics, moves in the opposite direction by potentially giving plans a federally sanctioned AI infrastructure to process denials more efficiently and at greater scale.
If you are currently enrolled in a Medicare Advantage plan and want to understand your prior authorization exposure right now, the most useful step is to review your plan's Evidence of Coverage document — a detailed booklet your insurer is required to provide each year, typically in late September or October. It lists every service category that requires prior authorization, the clinical criteria your plan uses to evaluate those requests, and the specific steps for filing an appeal. You can also call your plan's member services line and ask directly: which services require prior authorization, and what are the criteria for approval? Plans are required by federal regulation to answer that question clearly.
If you are approaching the Annual Enrollment Period — which runs October 15 through December 7 each year — and prior authorization practices are a concern given your health needs, Medicare.gov's Plan Finder tool allows you to compare plans in your area by prior authorization requirements and publicly reported denial rates. In 2026, CMS requires MA plans to disclose their prior authorization approval and denial rates, so that data is available before you commit to a plan for the following year. A plan with a lower denial rate and more transparent clinical criteria may justify a higher monthly premium if you rely heavily on specialist care, post-acute rehabilitation, or complex prescription regimens. The January 1 through March 31 Open Enrollment Period also allows MA enrollees to switch to a different MA plan or return to traditional Medicare once per year if your current plan's practices are not working for you.
For beneficiaries who depend on regular specialist visits, skilled nursing facility stays after a hospitalization, or high-cost specialty medications, the WISeR debate is not an abstract Washington policy argument. It is a question about who — or what — will be deciding whether your care gets approved, and how quickly. The legislative effort to block the pilot is ongoing, and its outcome will depend on whether Democrats can assemble enough votes to pass a resolution of disapproval or attach blocking language to a broader spending package. In the meantime, knowing your appeal rights in detail, reviewing your plan's prior authorization requirements annually, and using the public denial rate data now available on Medicare.gov are the most concrete protections available to you while this fight plays out.